ASSESSMENT OF ANTIBIOTIC SUSCEPTIBILITY IN PATIENTS WITH SEPTICEMIA CAUSED BY E. COLI AT THE NATIONAL HOSPITAL FOR TROPICAL DISEASE FROM 2015 TO 2020

Van Hung Nghiem, Van Hung Nghiem, Thi Dieu Ngan Ta

Main Article Content

Abstract

Background: The prevalence of septicemia caused by Escherichia coli (E. coli), a Gram-negative bacterium, is responsible for a high rate of mortality in Vietnam. The continuous emergence of various antibiotic-resistant strains of E. coli has turned septicemia treatment into an arduous challenge for doctors, even those with experience. Therefore, the assessment of the sensitivity of E. coli bacteria towards different antibiotics will essentially contribute to the selection of appropriate antibiotics as well as the improvement in treatment process.


Objective: Evaluate the sensitivity of E. coli towards a variation of antibiotics using samples isolated from patients with septicemia at National Hospital for Tropical Diseases (NHTD).


Subjects and methods: 101 patients diagnosed with septicemia by E. coli from July 2015 to June 2020 were recruited. The method of the study is a combination of cross-sectional, descriptive, retrospective, and prospective study.


Result: Among 101 patients, 88.12% of the patients were hospitalized within 1 week of the presence of the first clinical symptom; 9.9% had septic shocks and 60.4% had organ failures. E. Coli isolations had high resistance against Ampicillin (89.04%), Cotrimoxazol (74.39%), and Cefazolin (77.27%). The resistance against Ampicillin and Cotrimoxazol increased as time passed. Approximately 50% of the isolations were resistant against Cephalosporins generation III, IV and Quinolone. 51.49% of the isolations had Extended Spectrum Beta-Lactamase (ESBL). However, E. coliwas sensitive to Carbapenems (98% - 100%), Piperacillin with Tazobactam (93.1%), Amikacin (97.98%) and Nitrofurantoin (93.1%).


Conclusion: Septicemia patients are being monitored due to E. coli without microbiological results are recommended to use Carbapenems, Piperacillin, Tazobactam, Amikacin, and Nitrofurantoin. 

Article Details